HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

S.T. Dupont Signature Fragrance Duo Set To Make Its Mark

This article was originally published in The Rose Sheet

Executive Summary

S.T. Dupont will introduce Signature scents for men and women in April. The Paris-based firm, which is best known for its luxury pens, lighters and accessories, also markets a pair of S.T. Dupont scents.

You may also be interested in...



Jean Philippe European fragrance sales offset Cutex losses; Allou net income increases.

JEAN PHILIPPE INTER PARFUMS 50% FRAGRANCE SALES SECOND QUARTER GROWTH almost completely offsets the revenue declines resulting from the loss of the Cutex brand license, Jean Philippe reported Aug. 12. Fragrance sales from the French Inter Parfums subsidiary have exceeded Jean Philippe's expectations, the firm said, noting that the Burberrys of London fragrances, and specifically the Week end fragrance duo and body and hair care products, are driving sales. Week end was introduced under the Burberrys umbrella in Europe in March, Jean Philippe said

OCA Applauds Organic Board's Recommendation To USDA: "Outlaw Nanotech"

With a push from the Organic Consumers Association, the National Organic Standards Board is recommending that the use of nanotechnology be strictly prohibited from products certified under the National Organic Program

Beauty Claims Inch Closer To Pharma As Cosmeceutical Sector Expands

Though global market-size estimates differ, analysts at SupplySide West 2010 in Las Vegas agreed that cosmeceuticals remain a promising growth vehicle

Latest Headlines
See All
UsernamePublicRestriction

Register

RS007589

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel